Related Experiment Video
Updated: Apr 13, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury
Simiao Zhao1, Guangyan Mu1, Xiao Liu1
1Department of Pharmacy, Peking University First Hospital, Beijing, China.
Abstract:
Polymyxins serve as a 'last-line' defence against Gram-negative bacterial infections and are frequently used in critically ill patients with multidrug-resistant pathogens. However, polymyxin-associated acute kidney injury (PA-AKI) remains a major factor limiting their clinical application. This review examines the pathophysiology, risk factors and clinical management of PA-AKI, providing updated perspectives on its prevention and treatment. Reducing exposure to concomitant nephrotoxic agents, together with timely and standardized monitoring of serum creatinine, urine volume and polymyxin concentrations, plays a key role in mitigating the risk and progression of PA-AKI. Although several biomarkers show promise for the early prediction of PA-AKI and may enable earlier intervention, many have not yet undergone extensive clinical validation. There is a clear need to incorporate real-world evidence into clinical practice guidelines for polymyxin use. Further research should focus on identifying genetic risk factors for PA-AKI and developing novel polymyxin analogues with reduced nephrotoxicity.
Insights
Polymyxins are crucial for treating resistant infections but can cause kidney injury. Strategies like monitoring drug levels and avoiding other kidney-harming drugs can reduce this risk.
Area of Science:
- Nephrology
- Infectious Diseases
- Pharmacology
Background:
- Polymyxins are vital last-resort antibiotics for multidrug-resistant Gram-negative infections.
- Polymyxin-associated acute kidney injury (PA-AKI) significantly limits their clinical use, especially in critically ill patients.
Purpose of the Study:
- To review the pathophysiology, risk factors, and clinical management of PA-AKI.
- To provide updated perspectives on PA-AKI prevention and treatment strategies.
Main Methods:
- Literature review focusing on PA-AKI pathophysiology, risk factors, and management.
- Analysis of current evidence regarding prevention and treatment interventions.
- Discussion of emerging biomarkers and future research directions.
Main Results:
- Reducing exposure to nephrotoxic agents and consistent monitoring of renal function and drug levels are key to mitigating PA-AKI.
- Several biomarkers show potential for early PA-AKI prediction but require further clinical validation.
- Incorporating real-world evidence into guidelines and developing less nephrotoxic polymyxins are crucial.
Conclusions:
- Effective management of PA-AKI involves a multifaceted approach including risk factor reduction and vigilant monitoring.
- Further research is needed to validate predictive biomarkers and develop safer polymyxin alternatives.
- Clinical practice guidelines should integrate real-world data to optimize polymyxin therapy and minimize kidney injury.
Related Concept Videos
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care

